<DOC>
	<DOC>NCT01995513</DOC>
	<brief_summary>The purpose of this study is to determine if continued treatment with Enzalutamide is effective in patients with metastatic prostate cancer.</brief_summary>
	<brief_title>Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Men with metastatic castrationresistant prostate cancer Progressive disease on androgen deprivation therapy Patients must agree to continue androgen deprivation therapy with a GnRH agonist/antagonist throughout the study or have had a prior bilateral orchiectomy ECOG performance score ≤ 1 Estimated life expectancy of ≥ 12 months Prior cytotoxic chemotherapy, aminoglutethimide, ketoconazole, abiraterone, or enzalutamide for the treatment of prostate cancer Prior participation in a clinical trial of an investigational agent that inhibits the androgen receptor or androgen synthesis (unless the treatment was placebo) History of brain metastasis, active leptomeningeal disease or seizure Severe cardiovascular or hepatic disease Pituitary or adrenal dysfunction</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>